<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01424124</url>
  </required_header>
  <id_info>
    <org_study_id>YHD001-201</org_study_id>
    <nct_id>NCT01424124</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of YHD001 in Asthma</brief_title>
  <official_title>Randomized, Double-blind, Placebo/Active-controlled, Multi-center Clinical Trial to Investigate the Safety/Tolerability and Efficacy of YHD001 Following 8 Weeks Oral Administration of YHD001 in Patients With Partially Controlled Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yuhan Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective is to evaluate the safety/tolerability and efficacy of YHD001 compared to
      singulair or placebo in patients (n=96) with partially controlled asthma.

      The study will conduct with 4 comparative groups orally treated with YHD001 dose level
      1(t.i.d.), YHD001 dose level 2(t.i.d.), singulair 10mg(q.d.) or Placebo for 8 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Singulair: Montelukast sodium (leukotriene modulator)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline of FEV1 at week 4</measure>
    <time_frame>Baseline, week 4</time_frame>
    <description>FEV1: Forced Expiratory Volume In One Second</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of FEV1 at week 8</measure>
    <time_frame>Baseline, week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of PEFR at week 8</measure>
    <time_frame>Baseline, week 8</time_frame>
    <description>PEFR: Peak Expiratory Flow Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of ACT Score at week 8</measure>
    <time_frame>Baseline, week 8</time_frame>
    <description>ACT: Asthma control test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of using rescue medication(b-Agonist) at week 8</measure>
    <time_frame>Baseline, week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety assessment</measure>
    <time_frame>week 9</time_frame>
    <description>Comparison of the adverse event profiles throughout the course of the study</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>YHD001 dose level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>YHD001 dose level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Singulair</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YHD001 dose level 1</intervention_name>
    <description>Tablet, three times daily / 8 weeks</description>
    <arm_group_label>YHD001 dose level 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YHD001 dose level 2</intervention_name>
    <description>Tablet, three times daily / 8 weeks</description>
    <arm_group_label>YHD001 dose level 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Singulair</intervention_name>
    <description>Tablet, one times daily / 8 weeks</description>
    <arm_group_label>Singulair</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablet, one times daily / 7 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of signed written informed consent

          -  Acceptable medical history, physical exam,laboratory tests and EKG, during screening

          -  Nonsmoking (for longer than 1 year) patients with asthma

          -  Reversible airways obstruction (an increase in FEV1 absolute value of 12% or greater)
             20 to 30 minutes after inhalation of bâˆ’agonist

          -  FEV1 between 50% and 85% of the predicted value (withholding short-acting, inhaled
             b2-adrenergic agonist for 6 hours)

        Exclusion Criteria:

          -  History of any clinically significant disease

          -  History of drug/chemical/alcohol abuse

          -  Active upper respiratory tract infection within 3 weeks, emergency room treatment for
             asthma within 1 month, or hospitalization for asthma within 3 months of the prestudy
             visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2011</study_first_submitted>
  <study_first_submitted_qc>August 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2011</study_first_posted>
  <last_update_submitted>July 8, 2014</last_update_submitted>
  <last_update_submitted_qc>July 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

